miR-15a and miR-16 supplementation as a potential remedy for ovarian cancer

The annual incidence of ovarian cancer is 204,000, causing 125,000 deaths per year (1). While early stages of the disease can usually be cured by surgery, non-metastatic disease tends to remain asymptomatic and suitable screening strategies are not available. Once distant metastasis has occurred, the 5-year survival rate is below 20%. The most common form, epithelial ovarian cancer (EOC) is thus the most lethal genuinely gynaecological tumour.